OTCMKTS:BVNRY Bavarian Nordic A/S (BVNRY) Stock Price, News & Analysis $11.96 -0.24 (-1.97%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesShort Interest Get Bavarian Nordic A/S alerts: Email Address About Bavarian Nordic A/S Stock (OTCMKTS:BVNRY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bavarian Nordic A/S alerts:Sign Up Key Stats Today's Range$11.84▼$12.0850-Day Range$8.50▼$13.9552-Week Range$5.95▼$14.60Volume14,897 shsAverage Volume34,823 shsMarket Capitalization$2.80 billionP/E Ratio18.99Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewBavarian Nordic A/S is a fully-integrated biotechnology company focused on vaccination technology. The company’s work is built around two primary platforms that provide numerous benefits to the health industry and individuals. The company’s primary technology is MVA-BN which stands for Modified Vaccine Ankara-Bavarian Nordic. This vaccination platform is a non-replicating platform, meaning that live-virus vaccines cannot reproduce and spread within the host. This is central to the platform's high tolerance rate. MVA-BN is approved as a smallpox and monkeypox vaccine in the US, Canada, and the EU. It is also included in the US Strategic National Stockpile and is being used worldwide to control the 2022 Monkeypox outbreak.Bavarian Nordic is headquartered in Hellerup, Denmark with manufacturing sites in Denmark and Germany. The company maintains offices in Switzerland, the UK, Japan, and North Carolina in the United States. The company was incorporated in 1992 and had 4 approved products under 7 brand names available for use. Its MVA-BN non-replicating smallpox and monkeypox vaccines are available under the IMVAMUNE, IMVANEX and JYNNEOS names.The company’s second platform is the Vaccinia-Fowlpox-TRICOM platform for treating cancers. The platform can be targeted to attack specific markers found in numerous cancers. The company’s other marketable vaccines are Rabipur for rabies, MVABEA for Ebola and Marburg Hemorrhagic fever, and Encepur for tick-borne encephalitis.The company’s pipeline has 4 potential candidates for the market. These include a freeze-dried version of MVA-BN for smallpox, MVA-BN for RSV (respiratory infection), and TAEK-VAC for certain cancers. The company’s COVID-19/SARS vaccine boosters have shown effectiveness 6 months after dosing. Written by Jeffrey Neal JohnsonRead More… Are You Ready for a Small-Cap Rally? (Ad)Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt industries worth over $46 trillion. What's even more intriguing?Click here to uncover how you can get in on the ground floor. Receive BVNRY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bavarian Nordic A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address BVNRY Stock News HeadlinesGeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?GeoVax Labs has seen its shares rise enormously over the past few days after an announcement from the World Health Organization relevant to one of its drugs.August 20, 2024 | marketbeat.comEMA approves Bavarian Nordic’s mpox vaccine for teenagersSeptember 20 at 2:26 PM | finance.yahoo.comThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make HUGE gains. Now, I'm about to reveal the #1 crypto for September 2024. September 20, 2024 | Crypto 101 Media (Ad)Bavarian Nordic Gets EMA Approval Of Mpox Vaccine For AdolescentsSeptember 19 at 6:23 PM | markets.businessinsider.comBavarian Nordic mpox shot gains approval for adolescents in EUSeptember 19 at 6:23 PM | msn.comBavarian Nordic Receives EMA Approval of Mpox Vaccine for AdolescentsSeptember 19 at 9:45 AM | globenewswire.comGavi to obtain 500,000 mpox vaccine doses from Bavarian NordicSeptember 19 at 5:49 AM | finance.yahoo.comGavi to buy 500,000 mpox vaccine doses from Bavarian NordicSeptember 18 at 4:49 AM | reuters.comSee More Headlines BVNRY Stock Analysis - Frequently Asked Questions How have BVNRY shares performed this year? Bavarian Nordic A/S's stock was trading at $8.7450 on January 1st, 2024. Since then, BVNRY shares have increased by 36.8% and is now trading at $11.9625. View the best growth stocks for 2024 here. How were Bavarian Nordic A/S's earnings last quarter? Bavarian Nordic A/S (OTCMKTS:BVNRY) released its quarterly earnings results on Thursday, August, 22nd. The company reported $0.16 earnings per share (EPS) for the quarter. The firm earned $205.99 million during the quarter. Bavarian Nordic A/S had a trailing twelve-month return on equity of 12.50% and a net margin of 11.50%. How do I buy shares of Bavarian Nordic A/S? Shares of BVNRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Last Earnings8/22/2024Today9/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolOTCMKTS:BVNRY CUSIPN/A CIKN/A Webwww.bavarian-nordic.com Phone(453) 326-8383Fax45-3326-8380Employees1,379Year Founded1994Profitability EPS (Most Recent Fiscal Year)$0.63 Trailing P/E Ratio19.37 Forward P/E Ratio23.47 P/E GrowthN/ANet Income$214.20 million Net Margins11.50% Pretax Margin11.75% Return on Equity12.50% Return on Assets9.05% Debt Debt-to-Equity RatioN/A Current Ratio1.48 Quick Ratio1.03 Sales & Book Value Annual Sales$1.02 billion Price / Sales2.79 Cash Flow$2.05 per share Price / Cash Flow5.95 Book Value$6.41 per share Price / Book1.90Miscellaneous Outstanding Shares234,350,000Free FloatN/AMarket Cap$2.86 billion OptionableNot Optionable Beta1.70 Social Links 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (OTCMKTS:BVNRY) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in SeptemberWith thousands of cryptocurrencies out there, it's crucial to focus on the ONE that has the potential to make ...Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredHow the US Will Win the Great Lithium RaceChina spent $60B+ on lithium infrastructure in the past decade. It possesses 7.9% of the world’s supply, but i...DealMaker | SponsoredThe Perfect Storm for an EV RevoltWith constant talk about Artifical Intelligence, inflation, and the upcoming election clogging the airwaves......Eagle Publishing | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bavarian Nordic A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Bavarian Nordic A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.